5.6% said they used Liraglutide, 1.3% said they used Saxenda, and 1.4% said they did not remember the name of the GLP-1 they used
How Common Is Nausea During Treatment Nausea was reported in approximately 4060% of participants receiving mid-to-high doses in the Phase 2 trial, with most episodes classified as mild to moderate and occurring early in treatment or after dose increases
Clinical Benefits and Mechanisms of GLP-1RAs In this review, researchers examine the indications, benefits, risks, and prescribing considerations of GLP-1RAs, aiming to equip NPs with practical, evidence-based guidance to optimize their use in clinical practice
This suggests that the antioxidant response provided by NRF2 is not required for liver survival in the absence of GSH
Identifying these can confirm if your thyroid issue is autoimmune (like Hashimotos)